Abstract

For a long time cancer immunotherapy was overshadowed by chemotherapy and radiotherapy. Recently, “Science”, one of the world’s top scientific journals, named the stimulation of the body’s own immune system to fight cancer cells as the “breakthrough of the year”. In Germany, Switzerland and Austria, extracts derived from mistletoe (Viscum album L.) such as Iscador, Abnobaviscum, Helixor, Iscar, Iscucin and Isorel have been used in oncology for many years. These extracts have immunomodulating and immunostimulating properties, as demonstrated by experimental studies as well as in clinical trials. The aim of our paper is to present immunological disorders associated with cancer, which can be counteracted by treatment with extracts derived from mistletoe. Although these drugs cannot replace conventionalcancer treatment, they may improve the patient’s quality and length of life.

References

• 1. Abel U.: Incidence of infection and cancer risk. Dtsch. Med.Wschr., 1986; 111: 1987-1991
  Google Scholar
• 2. Aggarwal B.B., Shishodia S., Sandur S.K., Pandey M.K., Sethi G.:Inflammation and cancer: how hot is the link? Biochem. Pharmacol.,2006; 72: 1605-1621
  Google Scholar
• 3. Aptsiauri N., Cabrera T., Garcia-Lora A., Garrido F.: Cancer immuneescape: implications for immunotherapy, Granada, Spain,October 3-5, 2011. Cancer Immunol. Immunother., 2012; 61: 739-745
  Google Scholar
• 4. Auerbach L., Vaclavik-Fleck I., Dostal V., Kubista E.: Significanthigher level of activated NK-cells in patients with breast cancer receivinga Viscum album (mistletoe) extract during chemotherapy.Focus on Alternative and Complementary Therapies, 2004; 9: 3-4
  Google Scholar
• 5. Bauer C., Oppel T., Ruëff F., Przybilla B.: Anaphylaxis to viscotoxinsof mistletoe (Viscum album) extracts. Ann. Allergy AsthmaImmunol., 2005; 94: 86-89
  Google Scholar
• 6. Baxevanis C.N. Voutsas I.F., Soler M.H., Gritzapis A.D., TsitsilonisO.E., Stoeva S., Voelter W., Arsenis P., Papamichail M.: Mistletoe lectinI-induced effects on human cytotoxic lymphocytes. I. Synergismwith IL-2 in the induction of enhanced LAK cytotoxicity. Immunopharmacol.Immunotoxicol., 1998; 20: 355-372
  Google Scholar
• 7. Berger M.J., Dunlea L.J., Rettig M.E., Lustberg M.B., Phillips G.S.,Shapiro C.L.: Feasibility of stopping paclitaxel premedication aftertwo doses in patients not experiencing a previous infusion hypersensitivityreaction. Support. Care Cancer, 2012; 20: 1991-1997
  Google Scholar
• 8. Bergmann-Leitner E.S., Abrams S.I.: Influence of interferon γ onmodulation of Fas expression by human colon carcinoma cells andtheir subsequent sensitivity to antigen-specific CD8+ cytotoxic Tlymphocyte attack. Cancer Immunol. Immunother., 2000; 49: 193-207
  Google Scholar
• 9. Beuth J., Ko H.L., Gabius H.J., Burrichter H., Oette K., PulvererG.: Behavior of lymphocyte subsets and expression of activationmarkers in response to immunotherapy with galactoside-specificlectin from mistletoe in breast cancer patients. Clin. Investig., 1992;70: 658-661
  Google Scholar
• 10. Bock P.R., Friedel W.E., Hanisch J., Karasmann M., Schneider B.:Efficacy and safety of long-term complementary treatment withstandardized European mistletoe extract (Viscum album L.) in additionto the conventional adjuvant oncologic therapy in patientswith primary non-metastasized mammary carcinoma. Arzneimittelforschung,2004; 54: 456-466
  Google Scholar
• 11. Botti C., Seregni E., Ferrari L., Martinetti A., Bombardieri E.: Immunosuppressivefactors: role in cancer development and progression.Int. J. Biol. Markers, 1998; 13: 51-69
  Google Scholar
• 12. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L.,Hwu P., Drake C.G., Camacho L.H., Kauh J., Odunsi K., Pitot H.C., HamidO., Bhatia S., Martins R., Eaton K. i wsp.: Safety and activity ofanti-PD-L1 antibody in patients with advanced cancer. N. Engl. J.Med., 2012; 366: 2455-2465
  Google Scholar
• 13. Brandenberger M., Simões-Wüst A.P., Rostock M., Rist L., SallerR.: An exploratory study on the quality of life and individual copingof cancer patients during mistletoe therapy. Integr. Cancer Ther.,2012; 11: 90-100
  Google Scholar
• 14. Büssing A., Bischof M., Hatzmann W., Bartsch F., Soto-Vera D.,Fronk E.M., Gmeindl M., Stein G.M.: Prevention of surgery-inducedsuppression of granulocyte function by intravenous application ofa fermented extract from Viscum album L. in breast cancer patients.Anticancer Res., 2005; 25: 4753-4757
  Google Scholar
• 15. Büssing A., Kochskämper H., Rieger S., Schierholz J.M., SchlodderD., Schietzel M.: In vitro response of stimulated B-CLL lymphocytesof patients treated with Viscum album L. Extracts. AnticancerRes., 2007; 27: 4195-4200
  Google Scholar
• 16. Büssing A., Rosenberger A., Stumpf C., Schietzel M.: Developmentof lymphocyte subsets in tumor patients after subcutaneous administration of mistletoe extracts. Forsch. Komplementarmed.,1999; 6: 196-204
  Google Scholar
• 17. Büssing A., Stumpf C., Tröger W., Schietzel M.: Course of mitogenstimulatedT lymphocytes in cancer patients treated with Viscum albumextracts. Anticancer Res., 2007; 27: 2903-2910
  Google Scholar
• 18. Büssing A., Tröger W., Stumpf C., Schietzel M.: Local reactions totreatments with Viscum album L. extracts and their association withT-lymphocyte subsets and quality of life. Anticancer Res., 2008; 28:1893-1897
  Google Scholar
• 19. Cabrera T., López-Nevot M.A., Gaforio J.J., Ruiz-Cabello F., GarridoF.: Analysis of HLA expression in human tumor tissues. Cancer Immunol.Immunother., 2003; 52: 1-9
  Google Scholar
• 20. Chen I.H., Lai Y.L., Wu C.L., Chang Y.F., Chu C.C., Tsai I.F., Sun F.J., LuY.T.: Immune impairment in patients with terminal cancers: influenceof cancer treatments and cytomegalovirus infection. Cancer Immunol.Immunother., 2010; 59: 323-334
  Google Scholar
• 21. Choi S.H., Lyu S.Y., Park W.B.: Mistletoe lectin induces apoptosisand telomerase inhibition in human A253 cancer cells through dephosphorylationof Akt. Arch. Pharm. Res., 2004; 27: 68-76
  Google Scholar
• 22. Cihan Y.B., Arslan A., Ergul M.A.: Subtypes of white blood cellsin patients with prostate cancer or benign prostatic hyperplasia andhealthy individuals. Asian Pac. J. Cancer Prev., 2013; 14: 4779-4783
  Google Scholar
• 23. Coley W.B.: The treatment of inoperable sarcoma by bacterial toxins(the mixed toxins of the Streptococcus of erysipelas and the Bacillusprodigiosus). Proc. R. Soc. Med., 1910; 3:1-48
  Google Scholar
• 24. Coley W.B.: The treatment of sarcoma with the mixed toxins of erysipelasand Bacillus prodigiosus. Boston Med. Surg. J., 1908; 158: 175-182
  Google Scholar
• 25. Couzin-Frankel J.: Breakthrough of the year 2013. Cancer immunotherapy.Science, 2013; 342: 1432-1433
  Google Scholar
• 26. Dajee M., Lazarov M., Zhang J.Y., Cai T., Green C.L., Russell A.J.,Marinkovich M.P. Tao S., Lin Q., Kubo Y., Khavari P.A.: NF-κB blockadeand oncogenic Ras trigger invasive human epidermal neoplasia. Nature,2003; 421: 639-643
  Google Scholar
• 27. Duffell E.: Curative power of fever. Lancet, 2001; 358: 1276
  Google Scholar
• 28. Dunn G.P., Old L.J., Schreiber R.D.: The immunobiology of cancerimmunosurveillance and immunoediting. Immunity, 2004; 21: 137-148
  Google Scholar
• 29. Dziennik Urzędowy Ministra Zdrowia z dnia 12 kwietnia 2013, ObwieszczeniePrezesa Urzędu Rejestracji Produktów Leczniczych, WyrobówMedycznych i Produktów Biobójczych, poz. 15, s. 589
  Google Scholar
• 30. Enesel M.B., Acalovschi I., Grosu V., Sbarcea A., Rusu C., Dobre A.,Weiss T., Zarkovic N.: Perioperative application of the Viscum albumextract Isorel in digestive tract cancer patients. Anticancer Res., 2005;25: 4583-4590
  Google Scholar
• 31. Franz H., Ziska P., Kindt A.: Isolation and properties of three lectinsfrom mistletoe (Viscum album L.). Biochem. J., 1981; 195: 481-484
  Google Scholar
• 32. Gapuzan M.E., Yufit P.V., Gilmore T.D.: Immortalized embryonicmouse fibroblasts lacking the RelA subunit of transcription factorNF-κB have a malignantly transformed phenotype. Oncogene, 2002;21: 2484-2492
  Google Scholar
• 33. Geborek P., Nitelius E., Noltorp S., Petri H., Jacobsson L., Larsson L.,Saxne T., Leden I.: Population based studies of biological antirheumaticdrug use in southern Sweden: comparison with pharmaceutical sales.Ann. Rheum. Dis., 2005; 64: 1805-1807
  Google Scholar
• 34. Greenhough A., Smartt H.J., Moore A.E., Roberts H.R., WilliamsA.C., Paraskeva C., Kaidi A.: The COX-2/PGE2 pathway: key roles in thehallmarks of cancer and adaptation to the tumour microenvironment.Carcinogenesis, 2009; 30: 377-386
  Google Scholar
• 35. Grossarth-Maticek R., Frentzel-Beyme R., Kanazir D., Jankovic M.,Vetter H.: Reported herpes-virus infection, fever and cancer incidencein a prospective study. J. Chronic Dis., 1987; 40: 967-976
  Google Scholar
• 36. Grufferman S. Wang H.H., DeLong E.R., Kimm S.Y., Delzell E.S., FallettaJ.M.: Environmental factors in the etiology of rhabdomyosarcomain childhood. J. Natl. Cancer Ins., 1982; 68: 107-113
  Google Scholar
• 37. Hajto T.: Immunomodulatory effects of Iscador: a Viscum albumpreparation. Oncology, 1986; 43: 51-65
  Google Scholar
• 38. Hajtò T., Berki T., Pàlinkàs L., Boldizsàr F., Németh P.: Investigationof the effect of mistletoe (Viscum album L.) extract Iscador on theproliferation and apoptosis of murine thymocytes. Arzneimittelforschung,2006; 56: 441-446
  Google Scholar
• 39. Hajto T., Hostanska K., Gabius H.J.: Modulatory potency of theβ-galactoside-specific lectin from mistletoe extract (Iscador) on thehost defense system in vivo in rabbits and patients. Cancer Res., 1989;49: 4803-4808
  Google Scholar
• 40. Harmsma M., Grommé M., Ummelen M., Dignef W., Tusenius K.J.,Ramaekers F.C.: Differential effects of Viscum album extract Iscador Quon cell cycle progression and apoptosis in cancer cells. Int. J. Oncol.,2004; 25: 1521-1529
  Google Scholar
• 41. Harmsma M., Ummelen M., Dignef W., Tusenius K.J., RamaekersF.C.: Effects of mistletoe (Viscum album L.) extracts Iscador on cell cycleand survival of tumor cells. Arzneimittelforschung, 2006; 56: 474-482
  Google Scholar
• 42. Harris J., Sengar D., Stewart T., Hyslop D.: The effect of immunosuppressivechemotherapy on immune function in patients with malignantdisease. Cancer, 1976; 37: 1058-1069
  Google Scholar
• 43. Hegde P., Maddur M.S., Friboulet A., Bayry J., Kaveri S.V.: Viscumalbum exerts anti-inflammatory effect by selectively inhibiting cytokine-inducedexpression of cyclooxygenase-2. PLoS One, 2011; 6: e26312
  Google Scholar
• 44. Hoption Cann S.A., van Netten J.P., van Netten C.: Acute infectionsas a means of cancer prevention: opposing effects to chronic infections?Cancer Detect. Prev., 2006; 30: 83-93
  Google Scholar
• 45. Hugo F., Dittmar T., Treutler E.K., Zänker K.S., Kuehn J.J.: The Viscumalbum extract Iscador P does not cause an autocrine interleukin-6 loopin B-Non-Hodgkin’s Lymphoma cell lines. Onkologie, 2005; 28: 415-420
  Google Scholar
• 46. Hugo F., Schwitalla S., Niggemann B., Zanker K.S., Dittmar T.: Viscumalbum extracts Iscador P and Iscador M counteract the growthfactor induced effect in human follicular B-NHL cells and breast cells.Medicina Buenos Aires, 2007; 67: 90-96
  Google Scholar
• 47. Jessy T.: Immunity over inability: the spontaneous regression ofcancer. J. Nat. Sci. Biol. Med., 2011; 2: 43-49
  Google Scholar
• 48. Khwaja T.A., Dias C.B., Pentecost S.: Recent studies on the anticanceractivities of mistletoe (Viscum album) and its alkaloids. Oncology,1986; 43: 42-50
  Google Scholar
• 49. Kienle G., Kiene H., Albonico H.U.: Clinical studies on anthroposophicmistletoe therapy of cancer. W: Anthroposophic Medicine. Effectiveness,utility, costs, safety. Schattauer GmbH, 2006: 165-198
  Google Scholar
• 50. Kienle G.S., Grugel R., Kiene H.: Safety of higher dosages of Viscumalbum L. in animals and humans-systematic review of immune changesand safety parameters. BMC Complement. Altern. Med., 2011; 11: 72
  Google Scholar
• 51. Kiessling R., Pawelec G., Welsh R.M., Barry J.D., Ferrone S.: Havetumor cells learnt from microorganisms how to fool the immune system?Escape from immune surveillance of tumors and microorganisms:emerging mechanisms and shared strategies. Mol. Med. Today,2000; 6: 344-346
  Google Scholar
• 52. Kleef R., Hager D.: Fever, pyrogens and cancer. W: Baronzio G.F.,Hager E.D.: Hyperthermia in Cancer Treatment: A Primer. SpringerScience and Business Media. New York, 2006: 276-337
  Google Scholar
• 53. Kolmel K.F., Gefeller O., Haferkamp B.: Febrile infections and malignantmelanoma: results of a case-control study. Melanoma Res.,1992; 2: 207-211
  Google Scholar
• 54. Kozak W.: Znaczenie gorączki podczas infekcji: analizy klinicznei badania laboratoryjne. W: Geneza gorączki. Biologiczne mechanizmyi praktyka medyczna. Wydawnictwo Naukowe UMK, Toruń 2009:427-454
  Google Scholar
• 55. Kuttan G., Kuttan R.: Immunological mechanism of action of thetumor reducing peptide from mistletoe extract (NSC 635089) cellularproliferation. Cancer Lett., 1992; 66: 123-130
  Google Scholar
• 56. Li S.S.: Mistletoe lectins: telomerase inhibitors in alternative cancertherapy. Drug Discov. Today, 2002; 7: 896-897
  Google Scholar
• 57. Lowe D.B., Shearer M.H., Jumper C.A., Kennedy R.C.: Towards progresson DNA vaccines for cancer. Cell. Mol. Life. Sci., 2007; 64: 2391-2403
  Google Scholar
• 58. Lu T., Ramakrishnan R., Altiok S., Youn J.I., Cheng P., Celis E., PisarevV., Sherman S., Sporn M.B., Gabrilovich D.: Tumor-infiltrating myeloidcells induce tumor cell resistance to cytotoxic T cells in mice. J. Clin.Invest., 2011; 121: 4015-4029
  Google Scholar
• 59. Moraes M.C., Neto J.B., Menck C.F.: DNA repair mechanisms protectour genome from carcinogenesis. Front. Biosci., 2012; 17: 1362-1388
  Google Scholar
• 60. Mueller E.A., Anderer F.A.: A Viscum album oligosaccharide activatinghuman natural cytotoxicity is an interferon γ inducer. CancerImmunol. Immunother., 1990; 32: 221-227
  Google Scholar
• 61. Mueller E.A., Anderer F.A.: Chemical specificity of effector cell/tumorcell bridging by a Viscum album rhamnogalacturonan enhancingcytotoxicity of human NK cells. Immunopharmacology, 1990; 19: 69-77
  Google Scholar
• 62. Myklebust J.H., Irish J.M., Brody J., Czerwinski D.K., Houot R., KohrtH.E., Timmerman J., Said J., Green M.R., Delabie J., Kolstad A., AlizadehA.A., Levy R.: High PD-1 expression and suppressed cytokine signalingdistinguish T cells infiltrating follicular lymphoma tumors fromperipheral T cells. Blood, 2013; 121: 1367-1376
  Google Scholar
• 63. Newhouse M.L., Pearson R.M., Fullerton J.M., Boesen E.M., ShannonH.S.: A case control study of carcinoma of the ovary. Br. J. Prev.Soc. Med., 1977; 31, 148-153
  Google Scholar
• 64. Ogawa K., Hirai M., Katsube T., Murayama M., Hamaguchi K., ShimakawaT., Naritake Y., Hosokawa T., Kajiwara T.: Suppression of cellularimmunity by surgical stress. Surgery, 2000; 127: 329-336
  Google Scholar
• 65. Onizuka S., Tawara I., Shimizu J., Sakaguchi S., Fujita T., NakayamaE.: Tumour rejection by in vivo administration of anti-CD25 (Interleukin-2receptor α) monoclonal antibody. Cancer Res., 1999; 59: 3128-3133
  Google Scholar
• 66. Ott P.A., Hodi F.S., Robert C.: CTLA-4 and PD-1/PD-L1 blockade:new immunotherapeutic modalities with durable clinical benefit inmelanoma patients. Clin. Cancer Res., 2013; 19: 5300-5309
  Google Scholar
• 67. Pawelec G.: Tumour escape from the immune response. CancerImmunol. Immunother., 2004; 53: 843
  Google Scholar
• 68. Peng H.Y., Zhang Y.H., Han Y., Wang M.: Studies on the anticancereffects of total alkaloid from Viscum coloratum. Zhongguo Zhong YaoZa Zhi, 2005; 30: 381-387
  Google Scholar
• 69. Rasmussen L., Arvin A.: Chemotherapy-induced immunosuppression.Environ. Health Perspect., 1982; 43: 21-25
  Google Scholar
• 70. Remy W., Hammerschmidt K., Zanker K.S.: Tumortrager habenselten Infekte in der Anamnese. Med. Klin., 1983; 78: 95-98
  Google Scholar
• 71. Roberts N.J.Jr.: Impact of temperature elevation of immunologicdefenses. Rev. Infect. Dis., 1991; 13: 462-472
  Google Scholar
• 72. Roberts N.J.Jr.: The immunological consequences of fever. W: MackowiakP.A. (red.), Fever: Basic Mechanisms and Management. RavenPress, New York 1991: 125
  Google Scholar
• 73. Ronne T.: Measles virus infection without rash in children is relatedto disease in adult life. Lancet, 1985; 8419: 1-5
  Google Scholar
• 74. Seitz C.S., Lin Q., Deng H., Khavari P.A.: Alterations in NF-κB functionin transgenic epithelial tissue demonstrate a growth inhibitoryrole for NF-κB. Proc. Natl. Acad. Sci. USA, 1998; 95: 2307-2312
  Google Scholar
• 75. Soszyński D.: Mechanisms for development of tolerance to repeatedinjections of exogenous pyrogens. Postępy Hig. Med. Dośw.,2000; 54: 537-551
  Google Scholar
• 76. Spiegel W., Zidek T., Vutuc C., Maier M., Isak K., Micksche M.: Complementarytherapies in cancer patients: prevalence and patients’ motives.Wien. Klin. Wochenschr., 2003; 115: 705-709
  Google Scholar
• 77. Steinbrink K., Graulich E., Kubsch S., Knop J., Enk AH.: CD4+ andCD8+ anergic T cells induced by interleukin-10-treated human dendriticcells display antigen-specific suppressor activity. Blood, 2002;99: 2468-2476
  Google Scholar
• 78. Sznol M., Chen L.: Antagonist antibodies to PD-1 and B7-H1 (PDL1)in the treatment of advanced human cancer. Clin. Cancer Res.,2013; 19: 1021-1034
  Google Scholar
• 79. Tabiasco J., Pont F., Fournié J.J., Vercellone A.: Mistletoe viscotoxinsincrease natural killer cell-mediated cytotoxicity. Eur. J. Biochem.,2002; 269: 2591-600
  Google Scholar
• 80. Topalian S.L., Drake C.G., Pardoll D.M.: Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol.,2012; 24: 207-212
  Google Scholar
• 81. van der Weg F., Streuli R.A.: Use of alternative medicine by patientswith cancer in a rural area of Switzerland. Swiss Med. Wkly.,2003; 133: 233-240
  Google Scholar
• 82. van Hogerlinden M., Rozell B.L., Ahrlund-Richter L., Toftgard R.:Squamous cell carcinomas and increased apoptosis in skin with inhibitedRel/nuclear factor-κB signaling. Cancer Res., 1999; 59: 3299-3303
  Google Scholar
• 83. Van Steensel-Moll H.A., Valkenburg H.A., van Zanen G.E.: Childhoodleukemia and infectious diseases in the first year of life: A register-basedcase-control study. Am. J. Epidemiol., 1986; 124: 590-594
  Google Scholar
• 84. Vissoci Reiche E.M., Vargas Nunes S.O., Morimoto H.K.: Stress,depression, the immune system and cancer. Lancet Oncol., 2004; 5:617-625
  Google Scholar
• 85. Wang N., Feng Y., Wang Q., Liu S., Xiang L., Sun M., Zhang X., LiuG., Qu X., Wei F.: Neutrophils infiltration in the tongue squamous cellcarcinoma and its correlation with CEACAM1 expression on tumorcells. PLoS One, 2014; 9: e89991
  Google Scholar
• 86. Wasserman J., Blomgren H., Rotstein S., Petrini B., HammarströmS.: Immunosuppression in irradiated breast cancer patients: in vitro effectof cyclooxygenase inhibitors. Bull. N. Y. Acad. Med., 1989; 65: 36-44
  Google Scholar
• 87. Witzel L.: Anamnese und Zweiterkrankungen bei Patienten mitbosartigen Neubildungen. Med. Klin., 1970; 65: 876-879
  Google Scholar
• 88. Wrotek S., Kamecki K., Kwiatkowski S., Kozak W.: Cancer patientsreport a history of fewer fevers during infections than healthy controls.J. Pre-Clin. Clin. Res., 2009; 3: 031-035
  Google Scholar

Full text